The European Society of Cardiology recommends SGLT2 inhibitors to reduce heart-failure hospitalizations and improve cardiovascular outcomes [19,20], and the KDIGO guidelines likewise endorse their use as first-line therapy to slow the progression of diabetic kidney disease [21,22]. This evidence concerns the gene SLC5A2 and heart failure.